-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Star Enterprise of Chemical Machinery Equipment Network ] At the end of January, domestic pharmaceutical equipment companies such as Chutian Technology, Canaan Technology, and Tofflon successively disclosed 2020 performance forecasts.
All three companies are expected to achieve profitability in 2020.
Among them, Chutian Technology and Tofflon expect to double their net profit in 2020, and their performance exceeds expectations.
Chemical machinery and equipment network star enterprise chemical machinery and equipmentAll three companies are expected to achieve profitability in 2020.
Among them, Chutian Technology and Tofflon expect to double their net profit in 2020, and their performance exceeds expectations.
Chutian Technology: Net profit is expected to increase by 180%-240% year-on-year
Chutian Technology: Net profit is expected to increase by 180%-240% year-on-yearOn January 30, Chutian Technology disclosed its 2020 performance forecast.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be 183 million to 222 million yuan, a year-on-year increase of 180%-240% (after reorganization).
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be 183 million to 222 million yuan, a year-on-year increase of 180%-240% (after reorganization).
The company attributed its performance growth to: During the reporting period, the company adhered to the strategy of “one vertical, one horizontal, one platform”, served pharmaceutical customers, actively responded to customer needs, and effectively guaranteed order delivery.
At the same time, in recent years, the company has continued to increase R&D investment, strengthened the construction of process manufacturing platforms, and promoted internal management changes.
The company's product line technology and product performance have been steadily improved, and competitive advantages have gradually emerged.
At the same time, in recent years, the company has continued to increase R&D investment, strengthened the construction of process manufacturing platforms, and promoted internal management changes.
The company's product line technology and product performance have been steadily improved, and competitive advantages have gradually emerged.
In addition, during the reporting period, Chutian Technology also completed the merger and acquisition of ROMACO Group, which further promoted the strategic layout of corporatization.
Canaan Technology: Net profit is expected to increase by 20%~50% year-on-year
Canaan Technology: Net profit is expected to increase by 20%~50% year-on-year Canaan Technology released a performance forecast on the evening of January 29.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be 61.
577 million yuan to 76.
971 million yuan, a year-on-year increase of 20%-50%.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be 61.
577 million yuan to 76.
971 million yuan, a year-on-year increase of 20%-50%.
It is reported that during the reporting period, the company continued to strengthen the "solid preparation smart factory overall solution provider" and the strategic orientation of big health, and made every effort to ensure the advancement of projects in the pharmaceutical equipment and smart logistics industry.
The projects completed in this reporting period increased significantly compared with the previous period.
Among them, the contribution of solid preparation and powder technology projects continued to maintain steady growth; the demand for the downstream application industry of the pharmaceutical equipment smart factory business, the biological preparation pharmaceutical water equipment and liquid dispensing system business, and the smart logistics business segment remained strong, resulting in revenue and orders from the above business segments The growth is relatively fast.
Pharmaceutical water equipment The projects completed in this reporting period increased significantly compared with the previous period.
Among them, the contribution of solid preparation and powder technology projects continued to maintain steady growth; the demand for the downstream application industry of the pharmaceutical equipment smart factory business, the biological preparation pharmaceutical water equipment and liquid dispensing system business, and the smart logistics business segment remained strong, resulting in revenue and orders from the above business segments The growth is relatively fast.
At the same time, the company continues to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses across the industry chain to ensure that the company's sales and operating results continue to maintain steady growth.
East Fulong: Net profit is expected to increase by 210%~240% year-on-year
East Fulong: Net profit is expected to increase by 210%~240% year-on-year On the evening of January 29, Tofflon also issued a performance forecast.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be approximately 452 million to 496 million yuan, a year-on-year increase of 210% to 240%.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will be approximately 452 million to 496 million yuan, a year-on-year increase of 210% to 240%.
The main reason for the change in performance is that during the reporting period, the company vigorously promoted the layout and investment in the three major sectors of "pharmaceutical equipment", "medical technology and technology", and "food equipment engineering" around the development strategy of "systematization, digitization, and digitization".
Continue to innovate and quickly respond to customer needs.
During the epidemic, we will maintain effective communication with domestic and foreign customers through online methods to ensure the smooth delivery of system projects; continue to implement the precise management concept, implement digital transformation, and improve management.
Based on the above influences, the company's net profit during the reporting period is expected to increase by 210% to 240% over the same period of the previous year.
Continue to innovate and quickly respond to customer needs.
During the epidemic, we will maintain effective communication with domestic and foreign customers through online methods to ensure the smooth delivery of system projects; continue to implement the precise management concept, implement digital transformation, and improve management.
Based on the above influences, the company's net profit during the reporting period is expected to increase by 210% to 240% over the same period of the previous year.
Recently, Tofflon also disclosed the "Legal Opinion of Shanghai Jintiancheng Law Firm on the Company's 2021 Restricted Stock Incentive Plan (Draft).
" Kaiyuan Securities issued a research report on January 31 stating that it maintains the buy rating of Teflon.
The main reasons for the rating include: new products are gradually developing strength and are still in the performance release period; the equity incentive plan is released to demonstrate growth confidence.
" Kaiyuan Securities issued a research report on January 31 stating that it maintains the buy rating of Teflon.
The main reasons for the rating include: new products are gradually developing strength and are still in the performance release period; the equity incentive plan is released to demonstrate growth confidence.
Concluding remarks
Concluding remarks On the whole, the overall performance of the pharmaceutical equipment industry enterprises in 2020 has performed well.
Most large pharmaceutical machinery enterprises have achieved rapid development by actively promoting their own development strategies.
In the special period of 2020, many pharmaceutical machinery companies have adopted a number of measures to ensure the smooth delivery of customer orders, and some companies have implemented digital transformations and improved management through the implementation of precise management concepts.
Most large pharmaceutical machinery enterprises have achieved rapid development by actively promoting their own development strategies.
In the special period of 2020, many pharmaceutical machinery companies have adopted a number of measures to ensure the smooth delivery of customer orders, and some companies have implemented digital transformations and improved management through the implementation of precise management concepts.
Looking forward to 2021, with the upgrading of consumption levels and the increase of people's awareness of health care, the pharmaceutical industry will further develop rapidly, bringing opportunities to the upstream pharmaceutical equipment industry.
Compared with small and medium-sized pharmaceutical machinery companies with small R&D investment and weak technology, the industry believes that the competitive advantages of large pharmaceutical machinery companies may be further revealed.
Compared with small and medium-sized pharmaceutical machinery companies with small R&D investment and weak technology, the industry believes that the competitive advantages of large pharmaceutical machinery companies may be further revealed.
Original title: The 2020 performance forecast of the pharmaceutical equipment industry is gradually released, and the performance of many companies exceeds expectations!
